Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Narrative (Details)

v3.23.1
Commitments and Contingencies - Narrative (Details)
$ in Thousands
 12 Months Ended
Jul. 19, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
May 01, 2021
periods
Other Commitments [Line Items]        
Number of successive periods | periods       5
Agreement term, successive periods (in years)       1 year
Agreement term (in days)       90 days
Upfront license fee $ 50      
License agreement term (in days) 10 days      
Licensor royalties 3.00%      
Minimum royalty obligation $ 250      
General and administration   $ 34,385 $ 22,493  
Deferred Tax Assets, Valuation Allowance   824 $ 2,178  
License Agreement        
Other Commitments [Line Items]        
General and administration   $ 500    
License Agreement | Phase Three        
Other Commitments [Line Items]        
Additional payment of fee 900      
License Agreement | New Drug Application        
Other Commitments [Line Items]        
Additional payment of fee $ 1,000